Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 3/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | FCER2 | P06734 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 2/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8579403 | 0.91 | SMN1; SMN2 (0.41) | ZAP70SRCFFAR1SLC7A11CYP1A2 | |
| SCHEMBL4284137 | 0.89 | SLC7A11 (0.39) | ZAP70SRCFFAR1SLC7A11SIGMAR1 | |
| SCHEMBL6601402 | 0.85 | CAPN1 (0.39) | ZAP70SRCMAOBFCER2GHSR | |
| SCHEMBL6602122 | 0.85 | MC4R (0.42) | ZAP70SRCSLC7A11MAOBFCER2 | |
| SCHEMBL4282444 | 0.85 | CAPN1 (0.39) | ZAP70SRCMAOBFCER2GHSR | |
| SCHEMBL6606303 | 0.82 | SLC7A11 (0.38) | FFAR1SLC7A11SIGMAR1CYP1A2HDAC1 | |
| SCHEMBL6602371 | 0.81 | MC4R (0.40) | ZAP70SRCSLC7A11GHSRMME | |
| SCHEMBL5158806 | 0.77 | F2 (0.42) | FCER2 | |
| SCHEMBL5158813 | 0.77 | F2 (0.42) | FCER2 | |
| SCHEMBL6600950 | 0.77 | CAPN1 (0.37) | ZAP70SRCSLC7A11MAOBFCER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149512-A1 | Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases | NOVO NORDISK A/S (DK) | 2009-06-11 | — | — | US | claimed |
| EP-0805816-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2004-07-28 | — | — | EP | claimed |
| US-20090149512-A1 | Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases | NOVO NORDISK A/S (DK) | 2009-06-11 | — | — | US | disclosed |
| EP-1749208-A2 | FUNCTIONAL GHS-R ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005114180-A2 | FUNCTIONAL GHS-R ANTAGONISTS | NOVO NORDISK A/S (DK) | 2005-12-01 | — | — | WO | disclosed |
| EP-0907374-A1 | GROWTH HORMONE COMPONENT AND BONE ANTI-RESORPTIVE AGENT IN CYCLIC (COHERENCE) TREATMENT OF OSTEOPOROSIS | NOVO NORDISK A/S (DK) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997046252-A1 | GROWTH HORMONE COMPONENT AND BONE ANTI-RESORPTIVE AGENT IN CYCLIC (COHERENCE) TREATMENT OF OSTEOPOROSIS | NOVO NORDISK A/S (DK) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149512-A1 | Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases | GIPR, GHSR, GPR119 | ZAP70 3013/4885SRC 4072/4885FFAR1 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.